Advancing the Development of Novel Targets, Safe & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic

‍

‍

genOway's presentation on May 22, 2024 | 11:30 a.m. EDT:

How to Enhance Translatability of Immunotherapies in Preclinical Models?

• Focus on syngeneic humanized mouse models and BRGSF-HIS hCD34⁺ reconstituted mice featuring human lymphoid and myeloid compartments
• Characterization of the immune response in the mice
• Assessment of efficacy and safety induced by cell engagers